Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.5K citations · Full text

Medicine, Oncology, Urology +14

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

Medicine, Oncology, Urology +17

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Philip W. Kantoff, Thomas Schuetz, Brent A. Blumenstein et al. · Journal of Clinical Oncology · 2010 · 973 citations

Medicine, Immunology, Oncology +17

Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans

Daisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda et al. · Proceedings of the National Academy of Sciences · 2013 · 620 citations · Full text

Life Sciences, Immunology, Oncology +17